HCM
HUTCHMED DRCNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$2.27B
P/E Ratio
4.99
EPS
$2.65
Beta
0.38
52W High
$19.50
52W Low
$12.82
50-Day MA
$14.41
200-Day MA
$15.12
Dividend Yield
—
Profit Margin
83.30%
Forward P/E
50.25
PEG Ratio
0.00
About HUTCHMED DRC
HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
Fundamentals
| Revenue (TTM) | $548.51M |
| Gross Profit (TTM) | $63.87M |
| EBITDA | $-25.85M |
| Operating Margin | -13.20% |
| Return on Equity | 45.30% |
| Return on Assets | -1.62% |
| Revenue/Share (TTM) | $3.19 |
| Book Value | $7.20 |
| Price-to-Book | 1.83 |
| Price-to-Sales (TTM) | 4.14 |
| EV/Revenue | 1.819 |
| EV/EBITDA | 1.94 |
| Quarterly Earnings Growth (YoY) | -98.10% |
| Quarterly Revenue Growth (YoY) | -16.50% |
| Shares Outstanding | $171.95M |
| Float | $508.43M |
| % Insiders | 0.01% |
| % Institutions | 3.06% |
Historical Volatility
HV 10-Day
36.98%
HV 20-Day
32.89%
HV 30-Day
34.54%
HV 60-Day
32.83%
HV Rank
42.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($22.85 target)
1
Strong Buy9
Buy2
Hold1
SellMore HEALTHCARE Stocks
Data last updated: 5/5/2026